ea0081p148 | Pituitary and Neuroendocrinology | ECE2022
Milano Stephane
, Kurasaki Haruaki
, Tomiyama Tatsuya
, Reid Patrick
, Jan Van der Lely Aart
, Culler Michael D.
Medical treatment of acromegaly is based on either suppressing pituitary GH secretion or inhibiting GH action by preventing interaction with its receptor in order to suppress the elevated levels of IGF1. AZP-3813 is a 16-amino acid, bicyclic peptide antagonist of the GH receptor (GHR) derived from peptide sequences discovered using a unique, cell-free in vitro transcription-translation system screened against the human GHR, and that was optimized by rational design to increase...